06:15 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
17:49 , Aug 8, 2018 |  BC Extra  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...
23:38 , Jul 24, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A screening method using non-coding SNPs from genome-wide association studies (GWAS) could help identify new drug targets. The method involves five steps: creating double-stranded 31-base pair DNA constructs with each GWAS-identified...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Patient sample and mouse studies suggest gene editing of CD40L cDNA in autologous hematopoietic stem cells (HSCs) could help treat X-linked hyper-IgM syndrome (XHIM), which is caused by CD40L mutations. In patient-derived T cells,...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
02:28 , Mar 9, 2018 |  BC Innovations  |  Product R&D

Chips for tox

After several years’ pushing from FDA, NIH and DARPA for more predictive preclinical tox tests, organ-on-a-chip companies are close to demonstrating their models can detect signals missed in animals. While replacing animals is nowhere in...
17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

MedImmune spins out autoimmune play Viela

The MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of MedImmune’s Respiratory, Inflammation & Autoimmunity...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor...